Medipure Pharmaceuticals Overview
- Founded
- 2014
- Status
- Private
- Employees
- 26
- Latest Deal Type
- Later Stage VC
- Investors
- 1
Medipure Pharmaceuticals General Information
Description
Developer of proprietary endocannabinoid system-based prescription drugs intended for targeted diseases by regulating specific molecular mechanisms. The company develops proprietary drugs that target specific disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis, and dermatology, thereby helping physicians and healthcare providers in providing affordable treatment for targeted diseases with minimized side effects.
Contact Information
Website
www.medipurepharmaceuticals.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Primary Office
- 302-267 West Esplanade Avenue
- North Vancouver, British Columbia V7M 1A5
- Canada
+1 (877) 000-0000
Medipure Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC | 01-Dec-2021 | Completed | Generating Revenue |
Medipure Pharmaceuticals Patents
Medipure Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020218381-A1 | Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product | Pending | 07-Feb-2019 | 00000000000 | |
| CA-3129368-A1 | Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product | Pending | 07-Feb-2019 | 00000000000 | |
| US-11147805-B2 | Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product | Active | 07-Feb-2019 | 00000000000 | 00 |
| US-20200253947-A1 | Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product | Granted | 07-Feb-2019 | 00000000000 | |
| US-20200253948-A1 | Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product | Abandoned | 07-Feb-2019 | A61K31/4525 |
Medipure Pharmaceuticals Executive Team (4)
Medipure Pharmaceuticals Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Walter Berukoff | Medipure Pharmaceuticals | Chairman | 000 0000 |
Medipure Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialMedipure Pharmaceuticals Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| LYVC | Venture Capital | Minority | 000 0000 | 000000 0 |